Literature DB >> 35462105

Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics.

Deborah M Cholon1, Martina Gentzsch2.   

Abstract

To find a cure for cystic fibrosis, there has been tremendous progress in the development of treatments that target the basic defect in the protein channel, CFTR. However, 10% of cystic fibrosis patients have rare CFTR mutations that are still without an approved CFTR-targeting drug. To identify relevant therapies for these patients, culture models using nasal, bronchial, and rectal tissue from individual patients allow functional, biochemical, and cellular detection of drug-rescued CFTR. Additionally, novel systems such as induced pluripotent stem cell-derived models are utilized to characterize CFTR mutations and identify treatments. State-of-the-art translational models were instrumental for CFTR modulator development and may become important for gene-based drug discovery and other novel therapeutic strategies.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35462105      PMCID: PMC9167699          DOI: 10.1016/j.coph.2022.102210

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   4.768


  97 in total

1.  CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells.

Authors:  A Hamosh; B J Rosenstein; G R Cutting
Journal:  Hum Mol Genet       Date:  1992-10       Impact factor: 6.150

2.  Detection of CFTR function and modulation in primary human nasal cell spheroids.

Authors:  John J Brewington; Erin T Filbrandt; F J LaRosa; Alicia J Ostmann; Lauren M Strecker; Rhonda D Szczesniak; John P Clancy
Journal:  J Cyst Fibros       Date:  2017-07-13       Impact factor: 5.482

3.  Culturing of human nasal epithelial cells at the air liquid interface.

Authors:  Loretta Müller; Luisa E Brighton; Johnny L Carson; William A Fischer; Ilona Jaspers
Journal:  J Vis Exp       Date:  2013-10-08       Impact factor: 1.355

4.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

5.  Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis.

Authors:  Gitte Berkers; Peter van Mourik; Annelotte M Vonk; Evelien Kruisselbrink; Johanna F Dekkers; Karin M de Winter-de Groot; Hubertus G M Arets; Rozemarijn E P Marck-van der Wilt; Jasper S Dijkema; Maaike M Vanderschuren; Roderick H J Houwen; Harry G M Heijerman; Eduard A van de Graaf; Sjoerd G Elias; Christof J Majoor; Gerard H Koppelman; Jolt Roukema; Marleen Bakker; Hettie M Janssens; Renske van der Meer; Robert G J Vries; Hans C Clevers; Hugo R de Jonge; Jeffrey M Beekman; Cornelis K van der Ent
Journal:  Cell Rep       Date:  2019-02-12       Impact factor: 9.423

6.  Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci.

Authors:  Jiafen Gong; Fan Wang; Bowei Xiao; Naim Panjwani; Fan Lin; Katherine Keenan; Julie Avolio; Mohsen Esmaeili; Lin Zhang; Gengming He; David Soave; Scott Mastromatteo; Zeynep Baskurt; Sangook Kim; Wanda K O'Neal; Deepika Polineni; Scott M Blackman; Harriet Corvol; Garry R Cutting; Mitchell Drumm; Michael R Knowles; Johanna M Rommens; Lei Sun; Lisa J Strug
Journal:  PLoS Genet       Date:  2019-02-26       Impact factor: 5.917

Review 7.  Recent progress in translational cystic fibrosis research using precision medicine strategies.

Authors:  Deborah M Cholon; Martina Gentzsch
Journal:  J Cyst Fibros       Date:  2017-10-04       Impact factor: 5.482

8.  Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants.

Authors:  Onofrio Laselva; Claire Bartlett; Alec Popa; Hong Ouyang; Tarini N A Gunawardena; Tanja Gonska; Theo J Moraes; Christine E Bear
Journal:  J Cyst Fibros       Date:  2020-07-30       Impact factor: 5.482

Review 9.  Cystic Fibrosis Human Organs-on-a-Chip.

Authors:  Herbert Luke Ogden; Hoyeol Kim; Kathryn A Wikenheiser-Brokamp; Anjaparavanda P Naren; Kyu Shik Mun
Journal:  Micromachines (Basel)       Date:  2021-06-25       Impact factor: 2.891

10.  In Vitro Induction and In Vivo Engraftment of Lung Bud Tip Progenitor Cells Derived from Human Pluripotent Stem Cells.

Authors:  Alyssa J Miller; David R Hill; Melinda S Nagy; Yoshiro Aoki; Briana R Dye; Alana M Chin; Sha Huang; Felix Zhu; Eric S White; Vibha Lama; Jason R Spence
Journal:  Stem Cell Reports       Date:  2017-12-14       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.